U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. KEBILIDI
  1. Vaccines, Blood & Biologics

STN: 125722
Proper Name: eladocagene exuparvovec-tneq
Tradename: KEBILIDI
Manufacturer: PTC Therapeutics
Indication:

  • For the treatment of adult and pediatric patients with aromatic L amino acid decarboxylase (AADC) deficiency.

Product Information

  • Package Insert - KEBILIDI
  • Demographic Subgroup Information – eladocagene exuparvovec-tneql - KEBILIDI
    Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Supporting Documents

 

Back to Top